SRPT logo

SRPTSarepta Therapeutics Inc

$14.90
$0.10
(0.67%)
Overnight
Updated: 08:00 PM EDT·Prev Close $15.00
EarningsAug 5
Mkt Cap$1.6B
Vol2.76M
News
all
press releases
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
SRPT vs. ARGX: Which Stock Is the Better Value Option?
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40...
Business Wire
News Placeholder
The Biotech Supercycle Is Here: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine
Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders. $LLY, $NVO, $NTHI, $BAC, $STT, $BCS, $IMVT, $SRPT, $MRNA, $CRSP
24-7 Market News
News Placeholder
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
Zacks
News Placeholder
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
Zacks
News Placeholder
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
Zacks
News Placeholder
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock
Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock...
Yahoo! Finance: News
News Placeholder
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.